Skip to content
Call Us Today! 1 (772) 595-9830 info@midwayresearch.com
FacebookTwitterLinkedInInstagram
Midway Research Center Logo Midway Research Center Logo Midway Research Center Logo
  • Home
  • About
  • Clinical Trials
    • Currently Enrolling Studies
    • Active, not recruiting Studies
    • What is a Clinical Trial?
    • Expectations
    • Studies Phases
    • Informed Consent
    • Closed Studies
  • Services
    • HIV
    • STD
    • HPV
    • Lipodystrophy
  • Journal Publications
  • Contact
  • Home
  • About
  • Clinical Trials
    • Currently Enrolling Studies
    • Active, not recruiting Studies
    • What is a Clinical Trial?
    • Expectations
    • Studies Phases
    • Informed Consent
    • Closed Studies
  • Services
    • HIV
    • STD
    • HPV
    • Lipodystrophy
  • Journal Publications
  • Contact

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

Home/Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults
Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adultsmidwayadmin2019-10-28T19:25:36+00:00

Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults

GS-US-380-1489 · Trial ·

Read more

© Copyright 2012 -    |   AVADA THEME BY THEMEFUSION   |   ALL RIGHTS RESERVED   |   POWERED BY WORDPRESS
FacebookTwitterLinkedInInstagram